Abstract
Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the ‘immunome’, the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a “hot spot” of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.
Keywords: cancer vaccines, DNA vaccines, immunotherapy, personalised medicine, preclinical models, targeted cancer therapies, tumor-specific antigens, chemotherapy, Tumor-associated-antigen
Current Gene Therapy
Title: Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Volume: 11 Issue: 5
Author(s): Sandra Iurescia, Daniela Fioretti, Vito Michele Fazio and Monica Rinaldi
Affiliation:
Keywords: cancer vaccines, DNA vaccines, immunotherapy, personalised medicine, preclinical models, targeted cancer therapies, tumor-specific antigens, chemotherapy, Tumor-associated-antigen
Abstract: Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the ‘immunome’, the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a “hot spot” of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.
Export Options
About this article
Cite this article as:
Iurescia Sandra, Fioretti Daniela, Michele Fazio Vito and Rinaldi Monica, Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma, Current Gene Therapy 2011; 11 (5) . https://dx.doi.org/10.2174/156652311797415863
DOI https://dx.doi.org/10.2174/156652311797415863 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Essential 2D and 3D Chemical Features for Discovery of the Novel Tubulin Polymerization Inhibitors
Current Topics in Medicinal Chemistry Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Roles of microRNAs in HIV-1 Replication and Latency
MicroRNA Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment
Recent Patents on Drug Delivery & Formulation Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): Still an Obscure Disease
Central Nervous System Agents in Medicinal Chemistry Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design